Effectiveness of Erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months

Onkologie

Volumn 35, Issue 1-2, 2012, Pages 18-22

  Saito, Haruhiro ^a   Murakami, Shuji ^a   Kondo, Tetsuro ^a   Oshita, Fumihiro ^a   Noda, Kazumasa ^a   Yamada, Kouzo ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Disease control rate; Erlotinib; Gefitinib; Lung adenocarcinoma; Lung cancer; Resistance

Indexed keywords

ERLOTINIB; GEFITINIB;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEUROPATHY; OVERALL SURVIVAL; SIDE EFFECT; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856837898     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000335736     Document Type: Article

References (23)

1. Janne PA, Engelman JA, Jhon BE, et al.: Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234. (Pubitemid 46211347)
2. Nick Thacher, Alex Chang, Purvish Parikh, et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537. (Pubitemid 41540110)
3. Shepherd FA, Pereira JR, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
4. Kim ES, Hirsh V, Mok T, Socinski MA, et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTERST): a randomized phase III trial. Lancet 2008;372:1809-1818.
5. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
7. Ares LP, Soulieres D, Melezinek I, et al.: Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Med 2010;14:51-69.
8. Li J, Zhao M, He P, et al.: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13:3731-3737. (Pubitemid 46955138)
9. Cho BC, Im CK, Park MS, et al.: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-2533.
10. Wong AS, Soong R, Seah SB, et al.: Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008; 3:400-404. (Pubitemid 351489481)
11. Lee DH, Kim SW, Yoom DH, et al.: Phase II study of erlotinib as a salvage treatment for non-smallcell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008;19:2039-2042.
12. Costa DB, Son K, Cho BC, et al.: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008;14:7060-7067.
13. Vasile E, Tibaldi C, Chella A, et al.: Erlotinib after failure of gefitinib in patients with advanced nonsmall cell lung cancer previously responding to gefitinib. J Thorac Oncol 2008;3:912-914.
14. Sim SH, Han SW, Oh DY, et al.: Erlotinib after gefitinib in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer 2009;65:204-207.
15. Zhou ZT, Xu XH, Wei Q, et al.: Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 2009;64: 1123-1127.
16. Wong MK, Lo AI, Lam B, et al.: Erlotinib as salvage after failure to first-line gefitinib in nonsmall cell lung cancer. Cancer Chemother Pharmacol 2010;65:1023-1028.
17. Kaira K, Naito T, Takahashi T, et al.: Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010;68:99-104.
18. Yeo WL, Riely GJ, Yeap BY, et al.: Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010;5: 1048-1053.
19. Kojima Y, Saito H, Sakuma Y, et al.: Correlations of thin-section computed tomographic, histopathological, and clinical findings of adenocarcinoma with a bubblelike appearance. J Comput Assist Tomogr 2010;34:413-417.
20. Kalikaki A, Koutsopulos A, Hatzidaki D, et al.: Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010;69:110-115.
21. Han AW, Kim TY, Hwang PG, et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501.
22. Wu M, Zhao J, Song SW, et al.: EGFR mutations are associated with prognosis but with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010;67:343-347.
23. Doebele R, Oton AB, Peled N, et al.: New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 2010;69:1-12.